8 November 2011, London, Manchester, Munich, Sydney, Boston: College Hill Life Sciences is delighted that its client Prosensa Therapeutics has been announced as the winner of the 2011 EuropaBIO award for “Most Innovative European Biotech SME”, against stiff competition. The award, now in its second year, was announced on 8th November 2011 and underlines Prosensa’s pioneering role in helping patients and their families affected by rare diseases.
College Hill is pleased to have supported Prosensa in its application for the award which recognises a European Biotech SME that has developed innovative solutions to technical, social and environmental problems. Other 2011 finalists included AiCuris, Biocentras, Cardio3 BioSciences and to_BBB.
Nicole Yost, Associate Partner, College Hill Life Sciences, and team leader for Prosensa commented: “If a journalist asked us to name a company that uses cutting edge molecular biology techniques; employs a personalised medicine approach; works alongside patients and advocacy groups and is developing orphan drugs for rare diseases, we could not find a better example than Prosensa Therapeutics. It fully deserves this award and to be recognised for the great work it is doing.”
Prosensa is a Dutch biopharmaceutical company focused on the discovery, development and commercialization of RNA modulating therapeutics correcting gene expression in rare diseases. Prosensa’s current focus is on developing a treatment for Duchenne muscular dystrophy (DMD), a rare, genetic, childhood disease that afflicts approximately 1 in 3,500 newborn boys. There is currently no available therapy for DMD. The Company’s lead product PRO051 (GSK 2402968) is in Phase III trials in collaboration with GlaxoSmithKline for the treatment of DMD.
In accepting the award, Hans Schikan, CEO of Prosensa said: “Over the last three years Prosensa has more than tripled its workforce, to 80 people, all of whom share one mission: to find a treatment for DMD.”
Recognising the role of College Hill in preparing the entry for the award, Mr Schikan said: “Thank you to the College Hill Life Sciences team who were instrumental in supporting us with our application and with many other opportunities to communicate our progress.”
“We are very pleased to have supported Prosensa in this award application and in ensuring that it’s ground-breaking work is recognised and understood by the pharma and investment communities and, of course, the patient groups to whom finding a treatment for DMD is so important”, added Ms Yost.
For further information:
Managing Partner, Life Sciences
+44 (0)20 7457 2020
+44 (0)7968 726 585
Associate Partner, Life Sciences
+44 (0)20 7457 2020
Prosensa is an innovative Dutch biopharmaceutical company focused on the discovery, development and commercialization of RNA modulating therapeutics correcting gene expression in rare diseases with a high unmet medical need. Prosensa’s focus is on developing a treatment for Duchenne muscular dystrophy (DMD). Prosensa’s technology is based on a collaboration with Leiden University Medical Center. In 2009 Prosensa entered into a strategic alliance for part of its DMD exon skipping program with GlaxoSmithKline. Prosensa’s lead compound (PRO051/GSK2402968), being developed by GSK, entered phase III clinical trials in January 2011. Prosensa is a privately held biopharmaceutical company, backed by a consortium of Abingworth, GIMV, Idinvest, LSP and MedSciences Capital.
For more information about Prosensa, please visit www.prosensa.com